Cellares to produce Cabaletta’s autoimmune CAR-T candidate 

Cel­lares an­nounced a new part­ner­ship with Ca­balet­ta Bio to man­u­fac­ture the biotech’s au­toim­mune CAR-T cell ther­a­py can­di­date through mid-stage clin­i­cal tri­als.

Us­ing its Cell Shut­tle au­to­mat­ed man­u­fac­tur­ing plat­form, Cel­lares plans to make Ca­balet­tas’s CD19-CAR T can­di­date, which is called CA­BA-201, through Phase I/II clin­i­cal tri­als. This in­cludes mul­ti­ple in­di­ca­tions: sys­temic lu­pus ery­the­mato­sus, myosi­tis, sys­temic scle­ro­sis and gen­er­al­ized myas­the­nia gravis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.